ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
about
Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Emerging Bcl-2 inhibitors for the treatment of cancer.Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.The TRAIL of oncogenes to apoptosis.The mitochondrial death pathway: a promising therapeutic target in diseasesOn the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinCombination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosomeDecreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer.Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival.Combined modality therapy with TRAIL or agonistic death receptor antibodies.TRAIL-mediated signaling in prostate, bladder and renal cancer.PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells.Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.The BH3 mimetic ABT-737 induces cancer cell senescence.ARC synergizes with ABT-737 to induce apoptosis in human cancer cells.ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.BH3 Mimetics for the Treatment of Prostate Cancer.Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment.ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cellsUnderstanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia
P2860
Q30544925-A6ADB650-F6EE-45DD-A4B7-2315858BD779Q33682689-6B8BACC6-8FBA-4A21-9D93-17F1347CE6C1Q34344093-F8175874-689C-4E08-BCE1-E7D74998200DQ34354511-665E81DB-EA32-40F0-8BD4-13D8D2CD3F58Q35831981-98180CA5-8A62-4337-9806-ED7C5BE61F31Q35853714-E34E0687-1A3F-494A-B3ED-269E3C1ACE02Q35966223-CA3EF3FA-01EE-4DB0-9E1C-39DE39CB21E0Q35972500-5B7AC649-D9FC-41DF-913D-FA195D8648BAQ36561621-7FCD3BE1-BF2F-421C-A89F-26C7F604506CQ36747304-7AB700A2-2E61-4744-821B-240202D293D9Q36913828-7FBEE37E-12BC-4FC4-87F1-4D64231190E2Q37333720-E6717264-09FE-4BC5-B985-1862C1840DEFQ37377166-60B244E2-03B6-46BE-AC91-1D54DB4B742BQ37420038-7EDD3634-D364-4E64-A690-EB9B588B1E1AQ37832083-FBA36A6F-5114-41A8-8E79-A42FB566F147Q37889112-807432C5-1661-47BC-BADC-82E5CB131507Q38926314-85E09950-F563-4C51-9468-D310A1398D25Q39137039-05EFA12A-1A6F-4793-9FB8-7F311FF890F3Q39236559-EC77155D-C2EE-48CB-800D-7479ABE8EF46Q39443671-846E6268-6A6E-4C0B-B064-6083DB7F6B27Q39450845-F4638E63-DC22-4026-8A83-CDDB089325B8Q39594397-39A4E268-2EF4-486A-9BB2-431C832878EAQ39630639-88D7804C-C1EE-444D-B5F0-B3D717027AA9Q39697805-365DEF51-B774-421E-A7F6-323EC1ED231FQ39879308-13858735-0A40-4ADE-9E96-E08EC9F156CCQ39881718-DE5CDA5A-8446-4A3F-9F57-27409A2BFBFFQ41463153-D959C5EB-FB48-4FB4-8882-B02E5D479F85Q42090480-6E2418D7-258B-4CB7-B6A3-FFA57379B2B7Q42094231-8A082271-EF94-4E64-A872-EBFE50BD5531Q42117299-89E86790-CA04-44C1-BE55-E4409460FA18Q42747951-953E5482-2FA9-4C93-B807-D65BCFE483CDQ58751919-C6548439-1221-4E14-8805-C9858E90FAC2
P2860
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
ABT-737 induces expression of ...... lls to TRAIL-induced apoptosis
@en
ABT-737 induces expression of ...... ls to TRAIL-induced apoptosis.
@nl
type
label
ABT-737 induces expression of ...... lls to TRAIL-induced apoptosis
@en
ABT-737 induces expression of ...... ls to TRAIL-induced apoptosis.
@nl
prefLabel
ABT-737 induces expression of ...... lls to TRAIL-induced apoptosis
@en
ABT-737 induces expression of ...... ls to TRAIL-induced apoptosis.
@nl
P2860
P356
P1476
ABT-737 induces expression of ...... lls to TRAIL-induced apoptosis
@en
P2093
Andrew S Kraft
Karthikeyan Kandasamy
P2860
P304
25003-25013
P356
10.1074/JBC.M802511200
P407
P50
P577
2008-07-03T00:00:00Z